![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
Catalysis SL |
---|---|
Information provided by: | Catalysis SL |
ClinicalTrials.gov Identifier: | NCT00502086 |
The purpose of the study is to evaluate whether Viusid, a nutritional supplement, reduce the mortality and the complications (ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, hepatic encephalopathy, gastrointestinal bleeding, sepsis and hepatocellular carcinoma) of patients with cirrhosis of the liver secondary to HCV infection in comparison with placebo, during 96 weeks of treatment.
Condition | Intervention | Phase |
---|---|---|
Cirrhosis Chronic Hepatitis C |
Dietary Supplement: Viusid (nutritional supplement) Other: Placebo |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Efficacy and Safety of Viusid, a Nutritional Supplement, in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection. A Randomized, Controlled and Double Blind Study. |
Enrollment: | 100 |
Study Start Date: | May 2005 |
Estimated Study Completion Date: | July 2009 |
Estimated Primary Completion Date: | July 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
I: Experimental
Viusid, three sachets daily during 96 weeks
|
Dietary Supplement: Viusid (nutritional supplement)
Viusid three sachets daily during 96 weeks
|
2: Placebo Comparator
Placebo three sachets daily during 96 weeks
|
Other: Placebo
Placebo three sachets daily during 96 weeks
|
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Cuba, Havana | |
National Institute of Gastroenterology | |
Plaza de la Revolución, Havana, Cuba, 10400 |
Principal Investigator: | Eduardo Vilar Gómez, PhD | National Institute of Gastroenterology, Havana, Cuba |
Responsible Party: | National Institute of Gastroenterology ( Eduardo Vilar Gómez ) |
Study ID Numbers: | VIUHCV-07 |
Study First Received: | July 13, 2007 |
Last Updated: | January 8, 2009 |
ClinicalTrials.gov Identifier: | NCT00502086 History of Changes |
Health Authority: | Cuba: National Coordinating Center of Clinical Trials (CENCEC) |
Chronic hepatitis C Cirrhosis of the liver Mortality Complications |
Health-related quality of live Hepatocellular carcinoma Nutritional supplement |
Liver Diseases Hepatitis, Chronic Carcinoma, Hepatocellular Fibrosis Hepatitis, Viral, Human Liver Cirrhosis Carcinoma |
Hepatitis Virus Diseases Digestive System Diseases Neoplasm Metastasis Hepatitis C Hepatocellular Carcinoma Hepatitis C, Chronic |
Liver Diseases RNA Virus Infections Hepatitis, Chronic Flaviviridae Infections Fibrosis Hepatitis, Viral, Human Liver Cirrhosis |
Hepatitis Virus Diseases Digestive System Diseases Pathologic Processes Hepatitis C Hepatitis C, Chronic |